Status:
COMPLETED
Ixabepilone Administered as an Enteric Coated Formulation.
Lead Sponsor:
R-Pharm
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.
Eligibility Criteria
Inclusion
- ECOG status of 0-2.
Exclusion
- Unable to swallow pills.
- Current or recent GI disease or GI surgery.
- Brain mets.
- Severe nerve damage.
- ANC \<1,500/mm3
- Platelets \<125K.
- Bilirubin \>=1.5 times the IULN.
- ALT/AST \>=1.5 times the IULN.
- Creatine \>1.5 times the IULN.
- Prior treatment with Ixabepilone.
- Strong use of CYPP450 drugs.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00309049
Start Date
April 1 2006
End Date
May 1 2007
Last Update
January 30 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Washington D.C., District of Columbia, United States
2
Local Institution
Detroit, Michigan, United States